Search Results
Your search for ,SEE matches 4660 pages
Showing 3051 - 3100Accumulation of Metabolite Fumarate May Be Linked to Hereditary Leiomyomatosis and Renal Cell Cancer
Researchers funded by the Medical Research Council (MRC) have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer, it leads to an epigenetic reprogramming that drives cancer, according to a study published by Sciacovelli et al in Nature. The tumor growth...
FDA Approves Ofatumumab in Combination With Fludarabine and Cyclophosphamide for Relapsed CLL
Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia...
Hypofractionated Radiotherapy: Balancing Benefits vs Risks in Men With Localized Prostate Cancer
Radiation for prostate cancer typically requires 40 to 45 daily treatments, given over 8 to 9 weeks. Long fractionation schemes are chosen for most cancers, because they allow for tumor killing while reducing the potential for injury to normal tissue. However, the radiobiology of prostate cancer...
Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer
A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...
ASCO, Conquer Cancer Foundation Congratulate 2016 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.1 million in grants and awards to nearly 250 promising oncology researchers at the 2016 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and...
Clinical Trials Actively Recruiting Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on chronic lymphocytic leukemia. These studies are investigating multiple combination chemotherapies; regimens for relapsed and/or refractory disease; the role of inhibitors;...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
ASCO’s 2016 Quality Training Program: Meet the First International Participant From Greece
Launched in 2014, ASCO’s Quality Training Program was developed to prepare oncology providers to design, implement, and lead successful quality-improvement activities in their practices. It is a 6-month program that includes a structured and facilitated improvement project selected by each...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream
Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration (FDA) approval of the DigniCap Cooling System and the growing acceptance of scalp-cooling methods in the United States may improve the quality of life for many patients receiving...
Inotuzumab Ozogamicin Shows Clear Benefit in Acute Lymphoblastic Leukemia
In patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the antibody-drug conjugate inotuzumab ozogamicin produced significantly more complete remissions and was a better bridge to transplant than treatment by physician’s choice, according to the final results of a phase III trial...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling, or COMET (EAQ152), to the NCI-MATCH (EAY131) trial already underway. Using feedback surveys before and after a patient undergoes tumor gene...
Preclinical Study Finds Etoposide May Damage Developing Ovaries of Female Fetuses
The chemotherapy drug etoposide may have adverse effects on the developing ovaries of female fetuses, according to a preclinical study of mouse cells published by Stefansdottir et al in BMC Cancer. Norah Spears, DPhil, the corresponding study author and Professor of Reproductive Physiology at the...
Report Tracks Cancer Trends by Race/Ethnicity in Los Angeles County for 37 Years
Prostate cancer and lung cancer have been the number 1 and 2 cancers among men. Stomach cancer, the third leading cause of cancer deaths worldwide, has been on a steady decline among Koreans and Japanese. Black men had the highest overall rates of cancer. Thyroid cancer has been on the rise, and...
Metabolic Imaging as a Method to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Tumor shrinkage is not the only measure of a successful anticancer therapy. A University of Colorado Cancer Center article published by Serkova et al in Frontiers in Oncology describes a promising alternative: metabolic imaging. Tumors rush their metabolism to grow and proliferate. By recognizing a ...
I’m the Luckiest Person in the World
July 2009 was the start of the worst 5-year period of my life, and I’m just grateful I am still here to tell you about it. I was preparing for brain surgery to remove an acoustic neuroma on the right side of my brain when I noticed a lump on my left thigh. Thinking I had pulled a muscle while...
Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making
Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...
Multiple Means to Realize the Benefits of Colorectal Cancer Screening
In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...
Measures of Success
I was raised to be an engineer. I grew up in an industrial community, worked summer jobs in a U.S. Steel chemical plant, and was good at science and math. My career choice was straightforward: I went to an engineering university. My first semester freshman year included a mandatory introduction...
Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life
At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...
Educating People About Clinical Trials May Improve Their Likelihood of Participation
The facts are well known: Although clinical trials are regarded as the gold standard to investigate whether a new treatment is safe and effective in patients—and have resulted in advances in cancer cures and increases in cancer survivorship—only 3% to 5% of patients enroll in these studies.1 The...
Making a Difference in the Lives of Others
Quyen D. Chu, MD, MBA, FACS, this year’s recipient of ASCO’s Humanitarian Award, lives by the axiom that “One person can make a positive difference in the lives of others.” Although the term has become cliché, the experiences in Dr. Chu’s life and oncology career prove just how profound and...
Safety Concerns Weigh Heavily in Elderly Patients With Cancer
Active pharmacovigilance in detecting and assessing the safety signals related to drugs and devices, and disseminating those findings to relevant stakeholders, is an important component in delivering safe, high-quality care in the cancer setting. To reach a better understanding of this issue,...
Reduced-Intensity Related-Donor Haploidentical vs HLA-Matched Sibling-Donor Hematopoietic Cell Transplantation in Lymphoma
In an analysis of the observational database of the Center for International Blood and Marrow Transplant Research reported in the Journal of Clinical Oncology, Nilanjan Ghosh, MD, PhD, of Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, and colleagues found that...
Daniel F. Hayes, MD, FASCO, Leader in Translational Research, Begins Term as ASCO President
In 1995, Daniel F. Hayes, MD, FASCO, gathered with several other oncologists at a conference center in San Francisco to begin writing the first-ever ASCO guidelines on cancer treatment. He and his colleagues felt like pioneers scouting uncharted frontier. “I’ll never forget, that first hour or so, ...
The Complexities of Care for Older Cancer Survivors
Integrated care, a focus on prevention and screening, and acknowledgment of comorbidities on the impact of treatment all play a critical role in the cancer survivorship of older patients, according to Martine Extermann, MD, PhD, a medical oncologist at Moffitt Cancer Center in Tampa, Florida....
More Focus Needed on Chemotherapy-Induced Nausea as a Cluster of Symptoms
Management of chemotherapy-induced vomiting has improved with the use of antiemetics, but chemotherapy-induced nausea remains a major clinical problem, according to Alex Molassiotis, RN, PhD, Professor and Head of the School of Nursing at The Hong Kong Polytechnic University. And, he added, the...
Use of Dexamethasone Mouthwash in Managing mTOR Inhibitor–Associated Stomatitis in Patients With Breast Cancer
Prophylactic use of dexamethasone mouthwash significantly minimized the incidence of all grades of stomatitis in postmenopausal women receiving everolimus (Afinitor, Zortress) and exemestane for the treatment of hormone receptor–positive metastatic breast cancer, according to data presented by...
ASCO Plenary Studies: Assessing the ‘Value’ of New Treatments
At the 2016 ASCO Annual Meeting, studies presented at the Plenary Session gave attendees new treatment strategies to employ back home. But in the emerging push to contain the cost of new cancer treatments, do the four interventions fit within the new “value framework” for oncology? Deborah Schrag, ...
The National Cancer Moonshot Lifts Off
Just 6 months after President Barack Obama announced the establishment of a National Cancer Moonshot Initiative to accelerate the pace of research discoveries, improve patient access and care, and encourage data-sharing, dozens of new initiatives to accomplish those and other goals were rolled out...
My Commitment to Helping Other Survivors of Childhood Cancers
When I was diagnosed with acute lymphocytic leukemia (ALL) at the age of 2 in 1974, not much was known about the cancer or the side effects of its treatment. Too young to understand what was happening to me, the burden fell to my parents and older sibling to protect and care for me. For more than...
Clinical Trials Actively Recruiting Patients With Acute Myeloid Leukemia
Phase I/II Study Title: A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First-Relapse AML Study Type: Phase I/II/interventional/parallel assignment Study Sponsor and Collaborators: Yale University,...
As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda
Low-dose computed tomography (CT) screening for lung cancer in high-risk groups is moving into the clinic in the wake of its approval by the U.S. Centers for Medicaid & Medicare Services. That does not mean, however, the discussion is over. As low-dose CT moves from research to everyday...
Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy
The National Cancer Policy Forum of the National Academies of Sciences took up the issue of lung cancer screening at its mid-June workshop. Greta Massetti, PhD, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), and chair of ...
Discovery of Fragment Length of Circulating Tumor DNA Might Increase Liquid Biopsy Sensitivity
The liquid biopsy may be a welcome reprieve from typical biopsies. The minimally invasive test could reduce the need for the sometimes painful and risky procedures involved in sampling tumors, particularly those that reside deep within the body. However, thus far, the utility of the test has been...
Road to Successful Use of Real-World Evidence for Drug Development Is Long and Rocky
Friends of Cancer Research (Friends) has been a leader in the push for better and faster cancer drug development. Now it is tackling the use of real-world evidence in clinical trials. This is the report of a meeting on the subject that took place on June 16 in Washington, DC.1 Real-world evidence...
The Metastatic Breast Cancer Project: Direct-to-Patient Research Initiative
A nationwide project is enlisting patients with breast cancer to share their tumor samples and clinical information. Launched in October 2015, the Metastatic Breast Cancer (MBC) Project has enrolled more than 2,000 patients from all 50 states and is yielding information that will be shared with...
Sarah S. Donaldson, MD, FASCO, Honored With Inaugural Women Who Conquer Cancer Mentorship Award
Sarah S. Donaldson, MD, FASCO, of Stanford University School of Medicine and Lucile Packard Children’s Hospital, is the recipient of the Inaugural Women Who Conquer Cancer Mentorship Award. Throughout her decades-long career, Dr. Donaldson has mentored countless trainees and young oncologists,...
Quick Takes on Promising New Approaches to Treating Breast Cancer
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Abemaciclib Trial The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib produced responses...
Selected Hematology Abstracts From the 2016 ASCO Annual Meeting
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymphoma, and central nervous system (CNS) lymphoma. For full details of these study abstracts, visit...
Expert Point of View: Sunil Verma, MD
Sunil Verma, MD, Professor and Head of the Department of Oncology and Medical Director of the Tom Baker Cancer Centre of the University of Calgary in Canada, was the study’s formal discussant. He cited several limitations of the study: It was an open-label study, was initially a phase II study but ...
Expert Point of View: Marc S. Ernstoff, MD
The field of studies of combination immunotherapies is exploding, and “the future looks bright, with currently 71 trials of combination therapy in melanoma,” said formal discussant of these trials Marc S. Ernstoff, MD, of Roswell Park Cancer Institute, Buffalo, New York. “We now know that...
Stress and Adverse Life Events Unlikely to Cause Breast Cancer
Day-to-day psychological stress and adverse life events are unlikely to increase a woman’s risk of developing breast cancer, according to a new prospective study published by Schoemaker et al in Breast Cancer Research. Women with breast cancer often consider stress as a likely cause of their ...
Swiss Study Examines Cost-Effectiveness of Nivolumab vs Docetaxel in Advanced Nonsquamous NSCLC
Nivolumab, a checkpoint inhibitor approved for patients with squamous and nonsquamous non–small cell lung cancer (NSCLC) in 2015, is not cost-effective when compared to treatment with docetaxel, chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of nivolumab is...
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
Study Finds Incidence of Mutations in DNA-Repair Genes Significantly Higher in Men With Metastatic Prostate Cancer
The incidence of mutations in DNA-repair genes was significantly higher among men with metastatic prostate cancer than among men with localized disease (11.8% vs 4.6%), according to a study by Pritchard et al reported in The New England Journal of Medicine. In addition, the frequency ...
Thriving With Cancer
Seven years ago, at age 44, I was the picture of health. I played tennis every day, went bike riding and lifted weights several times a week, and made sure I ate a healthy diet. The closest I had ever come to cancer was caring for my mother during her 2-year illness with esophageal cancer. As it...
AACR Awards Four Inaugural NextGen Grants for Transformative Cancer Research
The American Association for Cancer Research (AACR) congratulates the four recipients of the inaugural NextGen Grants for Transformative Cancer Research. The recipients were honored at the AACR Annual Meeting 2016, held April 16–20 in New Orleans. “The AACR is very proud to announce the first...
What’s Driving the Rising Rates of Colorectal Cancer in Young Adults?
The study statistics are alarming—and perplexing. According to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) colorectal cancer registry, colon cancer incidence among young adults aged 20 to 34 is expected to increase 90% by 2030, and the incidence of rectosigmoid...
Personalized Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging methodology that allows the increase of the radiotherapy dose to the tumor while protecting vulnerable vital organs.1 The delicate balance of administering the...
